Shingles Vaccine: Protection Beyond the Rash

Sometimes in clinic, a patient tells me something I never forget: “Doctor, I thought it was just a rash.” And the truth is, it is not. Shingles is not just a skin problem. It can bring intense pain, weeks or months of discomfort, and for some people, complications that deeply affect quality of life. During vaccine awareness season, this is exactly the kind of vaccine we need to talk about more: the shingles vaccine.

The essentials in 5 lines

• The shingles vaccine helps prevent a painful illness and one of its most feared complications.
• In adults age 50 and older, protection is strong and lasts for years.
• It can also benefit people who are immunocompromised or living with chronic conditions.
• Vaccination may lower the risk of shingles and postherpetic neuralgia.
• One action for today: if you are 50 or older, or have a condition that raises your risk, ask your clinician whether this vaccine is right for you.

Why this vaccine matters

Vaccination remains one of the most important and cost-effective public health tools in history. It protects individuals directly and, for many infectious diseases, also reduces exposure and transmission across communities (Shattock et al., 2024; Li et al., 2021). But when we talk about shingles vaccination, we should not lose sight of the human side of prevention: avoiding suffering before it starts.

Shingles happens when the varicella-zoster virus, the same virus that causes chickenpox, becomes active again later in life. We see it more often in older adults, in people with weakened immune systems, and in those living with certain chronic illnesses. The rash gets attention, but the lasting nerve pain is often the real burden. That complication, called postherpetic neuralgia, can disrupt sleep, mood, mobility, and daily life (de Oliveira Gomes et al., 2023; Cunningham et al., 2016).

What the shingles vaccine does

The recombinant zoster vaccine, known as RZV or Shingrix, has shown high and durable protection. Clinical trials and real-world studies consistently support its effectiveness in preventing shingles and reducing the risk of postherpetic neuralgia in adults age 50 and older (de Oliveira Gomes et al., 2023; Marra & Lalji, 2022; Harbecke et al., 2021).

In one real-world U.S. analysis, two doses of RZV were associated with about 74% effectiveness against shingles and 84% effectiveness against postherpetic neuralgia, with stable protection over four years (Tseng et al., 2025). One dose offered some protection, but clearly less than the full series. That is an important takeaway: the full two-dose series matters.

Age also matters. Shingles risk rises with age, and so does the likelihood of postherpetic neuralgia (Dooling et al., 2018). That is why routine vaccination is centered around adults 50 and older.

The conversation is getting bigger: brain and heart health

This is where things get especially interesting. Recent observational studies suggest shingles vaccination may be associated with a lower later risk of dementia, including vascular dementia and Alzheimer disease, as well as lower cardiovascular risk in some populations. In one analysis, vaccinated adults had about a 20% lower relative risk of dementia (Eyting M et al., 2025), and in another large population study, vaccination was associated with roughly 25% lower risk of adverse cardiovascular events (Lee S et al., 2025).

That does not mean we should oversell the vaccine as a dementia vaccine or a heart vaccine. The evidence does not support that kind of claim. But it does suggest that viral reactivation, inflammation, vascular health, and brain health may be more connected than we once believed. That matters.

As a family and lifestyle medicine physician, I see this as part of a bigger picture. Vaccination does not compete with healthy eating, movement, sleep, stress management, or strong social connection. It works alongside them. Prevention is strongest when we bring those pieces together.

Who benefits the most?

The clearest answer is adults age 50 and older. But they are not the only ones.

People who are immunocompromised also stand to benefit in a meaningful way. The U.S. Advisory Committee on Immunization Practices recommends RZV for adults age 19 and older who are or will be immunocompromised because of disease or therapy (Anderson et al., 2022). This includes people receiving chemotherapy, organ or stem-cell transplant recipients, people with advanced HIV, and patients using immunosuppressive treatment for autoimmune or inflammatory disease.

People living with chronic illnesses also deserve attention here. Diabetes, chronic kidney disease, rheumatoid arthritis, asthma, and chronic obstructive pulmonary disease are all linked to higher shingles risk in different settings (Dooling et al., 2018; Safonova et al., 2023). GOLD 2026 guidance even recommends shingles vaccination for people with COPD over age 50.

And there is another point many people do not realize: having shingles once does not mean you cannot get it again. A prior episode should not close the door on vaccination (Greenberg et al., 2022).

How to move forward

For immunocompetent adults age 50 and older, the standard recommendation is two doses of recombinant zoster vaccine given 2 to 6 months apart (Dooling et al., 2018; ACIP, 2025). For immunocompromised adults, the interval may be shortened to 1 to 2 months when faster protection is needed (Anderson et al., 2022).

If there has been a longer-than-ideal delay between doses, the series usually does not need to be restarted. Prior vaccination with the older live vaccine, Zostavax, does not replace the need for the recombinant vaccine, because RZV provides stronger protection (Greenberg et al., 2022; Dooling et al., 2018).

Timing matters too. When possible, patients should be vaccinated before starting immunosuppressive therapy. If that is not possible, clinicians may try to time vaccination for a period when immune response is likely to be stronger. After a recent shingles episode, vaccination is typically delayed until the acute phase has resolved.

What to expect after the shot

Most side effects are temporary. The most common ones include injection-site pain, fatigue, muscle aches, and feeling unwell for one to three days. These reactions are expected and usually brief. Overall, the benefits strongly outweigh these short-lived effects (Lutz & Caldera, 2025; de Oliveira Gomes et al., 2023).

Patients sometimes tell me, “I heard this vaccine can hit hard.” My answer is simple: yes, some people do feel it for a day or two. But that is not the real comparison. The real comparison is between a short-lived vaccine reaction and the very real possibility of a painful, disruptive shingles complication. That changes the conversation.

What if you saw this vaccine as protection for daily life?

That shift matters. Instead of waiting for pain to arrive, you step in early. You protect your sleep, your energy, your focus, your independence, and the parts of life that matter most. That is also lifestyle medicine: not only living longer, but living better.

At Dr. Dándote Salud, we believe health is built day by day. Choose health. Choose life. When vaccination is appropriate, it is not just another box to check. It is a practical, evidence-based way to care for your future self.

The message to take with you today

If you are 50 or older, or younger but living with immunosuppression or a chronic condition that increases your risk, this vaccine is worth discussing with your clinician. Not every rash is simple. Not every pain fades quickly. And not every preventive step needs to wait until something goes wrong.

The best medicine is often the kind that prevents suffering quietly.

Let’s keep the conversation going

Had you heard that the shingles vaccine may help protect against much more than a rash? Leave a comment and tell me your biggest question about shingles vaccination.

Scientific Sources

1. Shattock AJ, Johnson HC, Sim SY, et al. Contribution of Vaccination to Improved Survival and Health: Modelling 50 Years of the Expanded Programme on Immunization. Lancet. 2024.
2. Li X, Mukandavire C, Cucunubá ZM, et al. Estimating the Health Impact of Vaccination Against Ten Pathogens in 98 Low-Income and Middle-Income Countries From 2000 to 2030. Lancet. 2021.
3. de Oliveira Gomes J, Gagliardi AM, Andriolo BN, et al. Vaccines for Preventing Herpes Zoster in Older Adults. Cochrane Database Syst Rev. 2023.
4. Marra Y, Lalji F. Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines. Viruses. 2022.
5. Harbecke R, Cohen JI, Oxman MN. Herpes Zoster Vaccines. J Infect Dis. 2021.
6. Tseng HF, Sy LS, Ackerson BK, et al. Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults ≥50 Years in the United States. Clin Infect Dis. 2025.
7. Zerbo O, Bartlett J, Fireman B, et al. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. Ann Intern Med. 2024.
8. Sun Y, Kim E, Kong CL, et al. Effectiveness of the Recombinant Zoster Vaccine in Adults Aged 50 and Older in the United States: A Claims-Based Cohort Study. Clin Infect Dis. 2021.
9. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016.
10. Oxman MN, Levin MJ, Johnson GR, et al. A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. N Engl J Med. 2005.
11. Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR. 2018.
12. Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR. 2022.
13. Greenberg GM, Koshy PA, Hanson MJS. Adult Vaccination. Am Fam Physician. 2022.
14. Safonova E, Yawn BP, Welte T, Wang C. Risk Factors for Herpes Zoster: Should People With Asthma or COPD Be Vaccinated? Respir Res. 2023.
15. Lutz MK, Caldera F. Vaccination Outcomes and Recommendations Among Older Adults in a Gastroenterology and Hepatology Practice. Am J Gastroenterol. 2025.
16. Ghesquière W, Tessier D, Brown V, et al. Vaccination in Adults at-Increased Risk of Herpes Zoster in Canada: Insights From a Multidisciplinary Panel Consensus. Expert Rev Vaccines. 2025.
17. Lee S et al. Live zoster vaccination and cardiovascular outcomes: A nationwide, South Korean study. Eur Heart J. 2025.
18. Eyting M et al. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature. 2025.

🌍 This article is also available in Spanish. Please use the language switcher in the top menu.